Risk-Treatment Mismatch in the Pharmacotherapy of Heart Failure

Open Access

14 September 2005

journal article
research article
Published by American Medical Association (AMA) in JAMA

Vol. 294 (10) , 1240-1247
https://doi.org/10.1001/jama.294.10.1240

Abstract

Heart failure affects more than 5 million people in Canada and the United States and is associated with a high mortality rate.¹^,2 Medications shown to reduce the mortality and morbidity of this condition include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and β-adrenoreceptor antagonists.³^-5 These drug classes have been studied extensively and recommended strongly by disease management guidelines.⁶^,7 Given the proven mortality benefits of these drugs, it is important to ensure that patients at the highest risk of death receive these therapies.⁸^-12

Keywords

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
PHARMACOTHERAPY
HEART FAILURE
ADRENERGIC RECEPTOR
PATIENT DISCHARGE
LEFT VENTRICULAR EJECTION FRACTION
ANGIOTENSIN RECEPTOR ANTAGONISTS
ANGIOTENSIN-CONVERTING ENZYME
ANTAGONISTS

This publication has 0 references indexed in Scilit: